Gabriel Botella F, Labios Gómez M, Balaguer Martínez J V, Bort Martí J, Bataller Sifré R, Campos Cervera J M
Servicio de Medicina Interna., Hospital Clínico Universitario de Valencia.
An Med Interna. 1993 Jan;10(1):16-20.
Venous thromboembolism (VTE) is a frequent complication in hospitalized patients who have to stay in bed for long periods of time or with diseases favouring of low molecular weight (HLMW) developed during the past years have demonstrated that they are as effective as the non-fractionated heparins, but with the advantage of a better cutaneous absorption, greater bioavailability and plasmatic half-life, a more favourable antithrombotic/hemorrhagic ratio and a lower variability in the anticoagulant response to fixed doses. We have investigated the efficacy, efficiency and security of an HLMW (Enoxaparine) for the prevention of VTE, comparing it with an standard calcic heparin, subcutaneously administrated, in patients with non-surgical risk factors and more than 65 years of age. Based on our results, we cannot conclude that one therapy is better than the other, although the enoxaparine needs only one daily injection and it can be administrated in an out-patient basis for long periods of time, without the need of laboratory controls and the resulting cost savings.
静脉血栓栓塞症（VTE）是长期卧床或患有易引发低分子量疾病的住院患者常见的并发症。过去几年开发的低分子量肝素（HLMW）已证明其与普通肝素一样有效，但具有皮肤吸收更好、生物利用度更高、血浆半衰期更长、抗血栓/出血比例更有利以及固定剂量抗凝反应变异性更低的优势。我们研究了一种低分子量肝素（依诺肝素）预防VTE的疗效、有效性和安全性，并将其与皮下注射的标准钙肝素进行比较，研究对象为有非手术风险因素且年龄超过65岁的患者。基于我们的研究结果，我们无法得出一种治疗方法优于另一种的结论，尽管依诺肝素只需每日注射一次，且可在门诊长期给药，无需实验室监测，从而节省成本。
